Search results for " monohydrate"

showing 10 items of 534 documents

CCDC 1995535: Experimental Crystal Structure Determination

2020

Related Article: Hai Yi, Markus Albrecht, Fangfang Pan, Arto Valkonen, Kari Rissanen|2020|Eur.J.Org.Chem.||6073|doi:10.1002/ejoc.202001008

8-{[35-bis(trifluoromethyl)phenyl]methoxy}-2-methylquinolin-1-ium chloride monohydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 705738: Experimental Crystal Structure Determination

2009

Related Article: D.Meshcheryakov, V.Bohmer, M.Bolte, V.Hubscher-Bruder, F.Arnaud-Neu|2009|Chem.-Eur.J.|15|4811|doi:10.1002/chem.200802573

97979898-Tetramethyl-3435191-tetra-t-butyl-153147637995-hexaoxa-6822243840545670728688-dodeca-azapentadecacyclo[91.3.1.14549.0596.0914.01621.02530.03237.04146.04853.05762.06469.07378.08085.08994]octanonaconta-1(96)2491113161820252729323436414345485052575961646668737577808284899193-hexatriacontaene-72339557187-hexone acetonitrile ethanol ethyl acetate solvate monohydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

The effects of creatine supplementation on muscular performance and body composition responses to short-term resistance training overreaching

2003

To determine the effects of creatine supplementation during short-term resistance training overreaching on performance, body composition, and resting hormone concentrations, 17 men were randomly assigned to supplement with 0.3 g/kg per day of creatine monohydrate (CrM: n=9) or placebo (P: n=8) while performing resistance exercise (5 days/week for 4 weeks) followed by a 2-week taper phase. Maximal squat and bench press and explosive power in the bench press were reduced during the initial weeks of training in P but not CrM. Explosive power in the bench press, body mass, and lean body mass (LBM) in the legs were augmented to a greater extent in CrM ( P<or=0.05) by the end of the 6-week period…

AdultMalemedicine.medical_specialtyPhysiologyStrength trainingAdministration OralBlood PressureCreatineBench presschemistry.chemical_compoundHeart RatePhysiology (medical)Internal medicinemedicineHumansOrthopedics and Sports MedicineMuscle SkeletalPhysical Education and Trainingbusiness.industryOvertrainingFree androgen indexPublic Health Environmental and Occupational HealthGeneral MedicineCreatineOverreachingmedicine.diseaseAdaptation PhysiologicalHormonesEndocrinologychemistryDietary SupplementsBody CompositionPhysical EnduranceLean body massCreatine MonohydratebusinessPsychomotor PerformanceMuscle ContractionEuropean Journal of Applied Physiology
researchProduct

Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone p…

2018

BACKGROUND Long-acting injectable (LAI) antipsychotics can improve medication adherence and reduce hospitalisation rates compared with oral treatments. Paliperidone palmitate (PAL) and aripiprazole monohydrate (ARI) LAI treatments were associated with improvements in global functioning in patients with schizophrenia. OBJECTIVE The objective of this study was to assess the predictive factors of better overall functioning in patients with chronic schizophrenia and schizoaffective disorder treated with PAL and ARI. METHOD Enrolled were 143 (97 males, 46 females, mean age 38.24 years, SD = 12.65) patients with a diagnosis of schizophrenia or schizoaffective disorder, whom we allocated in two gr…

AdultMalemedicine.medical_specialtyaripiprazole monohydrate; global assessment of functioning; long-acting injectable antipsychotics; paliperidone palmitate; schizoaffective disorder; schizophrenia; neurology; neurology (clinical); psychiatry and mental health; pharmacology (medical)Global Assessment of FunctioningAripiprazoleSchizoaffective disorderPharmacyOutcome Assessment (Health Care)03 medical and health sciencesYoung Adult0302 clinical medicineglobal assessment of functioningInternal medicineOutcome Assessment Health CarePaliperidone PalmitatemedicineHumansPharmacology (medical)aripiprazole monohydratearipiprazole monohydrate; global assessment of functioning; long-acting injectable antipsychotics; paliperidone palmitate; schizoaffective disorder; schizophrenia; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Young Adult; Outcome Assessment (Health Care)Paliperidone Palmitatebusiness.industrylong-acting injectable antipsychoticsMiddle Agedschizoaffective disordermedicine.disease030227 psychiatryPsychiatry and Mental healthNeurologyPsychotic DisordersSchizophreniaDelayed-Action PreparationsSettore SECS-P/03 - Scienza delle FinanzeSchizophreniaChronic schizophreniaAripiprazoleFemaleNeurology (clinical)business030217 neurology & neurosurgeryDiagnosis of schizophreniamedicine.drugAntipsychotic AgentsHuman psychopharmacology
researchProduct

CCDC 258321: Experimental Crystal Structure Determination

2005

Related Article: M.L.Calatayud, J.Sletten, M.Julve, I.Castro|2005|J.Mol.Struct.|741|121|doi:10.1016/j.molstruc.2005.01.069

Aqua-(123-trioxocyclopent-4-en-45-diolato)-(22':6'2''-terpyridine)-nickel(ii) monohydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 200156: Experimental Crystal Structure Determination

2004

Related Article: J.Carranza, C.Brennan, J.Sletten, B.Vangdal, P.Rillema, F.Lloret, M.Julve|2003|New J.Chem.|27|1775|doi:10.1039/b301212n

Aqua-(oxalato)-(22'-biimidazole)-copper(ii) monohydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 170551: Experimental Crystal Structure Determination

2002

Related Article: H.Grove, J.Sletten, M.Julve, F.Lloret, L.Lezama, J.Carranza, S.Parsons, P.Rillema|2002|J.Mol.Struct.|606|253|doi:10.1016/S0022-2860(01)00891-2

Aqua-(oxalato-OO')-(1458912-hexa-azatriphenylene)-copper(ii) monohydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophreniaspectrum disorders: Findings f…

2020

This study, based on the 'Servizi Territoriali Associati per la Ricerca' (STAR) Network Depot Study nationwide baseline data, explored whether individual symptoms severity and clusters might influence the prescription of paliperidone palmitate 1-month (PP1M) vs. aripiprazole monohydrate. The Brief Psychiatric Rating Scale (BPRS) was used to assess psychopathology and relevant symptoms clusters. Drug Attitude Inventory, 10 items, was used to test attitude towards medications. Adherence to treatments was rated according to the Kemp seven-point scale. We assessed for eligibility 451 individuals and, among them, we included 195 subjects (n = 117 who started PPM1 and n = 78 aripiprazole monohydr…

Aripiprazole monohydrate; Long-acting injectable antipsychotics; Paliperidone palmitate; Schizophrenia; Adult; Antipsychotic Agents; Aripiprazole; Female; Health Knowledge Attitudes Practice; Humans; Male; Medication Adherence; Paliperidone Palmitate; Practice Patterns Physicians'; Schizophrenia; Schizophrenic Psychology; Young AdultAdultMaleLong-acting injectable antipsychoticmedicine.medical_specialtyHealth Knowledge Attitudes Practicemedicine.medical_treatmentAripiprazole monohydrate Long-acting injectable antipsychotics Paliperidone palmitate SchizophreniaAripiprazolePractice PatternsLong-acting injectable antipsychoticsMedication Adherence03 medical and health sciencesYoung Adult0302 clinical medicineAripiprazole monohydrate; Long-acting injectable antipsychotics; Paliperidone palmitate; SchizophreniaInternal medicineBrief Psychiatric Rating ScalemedicineHumansPharmacology (medical)Practice Patterns Physicians'AntipsychoticSettore MED/25 - PsichiatriaPaliperidone PalmitatePaliperidone palmitatePracticePhysicians'business.industryHealth KnowledgeAripiprazole monohydratemedicine.disease030227 psychiatryPsychiatry and Mental healthSchizophreniaAttitudesPropensity score matchingSchizophreniaObservational studyAripiprazoleFemaleSchizophrenic Psychologybusiness030217 neurology & neurosurgerymedicine.drugPsychopathologyAntipsychotic Agents
researchProduct

CCDC 249547: Experimental Crystal Structure Determination

2005

Related Article: M.Viciano, E.Mas-Marza, M.Poyatos, M.Sanau, R.H.Crabtree, E.Peris|2005|Angew.Chem.,Int.Ed.|44|444|doi:10.1002/anie.200461918

Chloro-(eta^4^-cyclo-15-octadiene)-hydrido-(bis(N-methyl-13-dihydridoimidazol-3-yl-2-ylidene)(ferrocenyl)methane)-iridium hexafluorophosphate monohydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 815937: Experimental Crystal Structure Determination

2012

Related Article: S.Majumder, S.Dutta, L.M.Carrella, E.Rentschler, S.Mohanta|2011|J.Mol.Struct.|1006|216|doi:10.1016/j.molstruc.2011.09.011

Diaqua-(22'-(12-phenylenebis((nitrilo)methylylidene))bis(6-ethoxyphenolato)-NN'OO')-iron(iii) nitrate monohydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct